13602-11-4Relevant academic research and scientific papers
A two-in-one pincer ligand and its diiron(II) complex showing spin state switching in solution through reversible ligand exchange
Samanta, Subhas,Demesko, Serhiy,Dechert, Sebastian,Meyer, Franc
, p. 583 - 587 (2015)
A novel pyrazolate-bridged ligand providing two {PNN} pincer-type compartments has been synthesized. Its diiron(II) complex LFe2(OTf)3(CH3CN) (1; Tf=triflate) features, in solid state, two bridging triflate ligands, with a terminal triflate and a MeCN ligand completing the octahedral coordination spheres of the two high-spin metalions. In MeCN solution, 1 is shown to undergo a sequential, reversible, and complete spin transition to the low-spin state upon cooling. Detailed UV/Vis and 19F NMR spectroscopic studies as well as magnetic measurements have unraveled that spin state switching correlates with a rapid multistep triflate/MeCN ligand exchange equilibrium. The spin transition temperature can be continuously tuned by varying the triflate concentration in solution.
Potential insulinominetic agents of zinc(II) complexes with picolinamide derivatives: Preparations of complexes, in vitro and in vivo studies
Ueda, Eriko,Yoshikawa, Yutaka,Ishino, Yoshio,Sakurai, Hiromu,Kojima, Yoshitane
, p. 337 - 340 (2002)
Following the finding of in vitro insulinominetic activities of new prepared Zn(II) complexes with amide ligands (2-picolinamide (pa-a) and 6-methyl-2-picolinmethylamide (6mpa-ma)) in isolated rat adipocytes treated with epinephrine in terms of inhibition of free fatty acid release, their blood glucose normalizing effects were observed on daily intraperitoneal injections for 14 d in a type 2 diabetes mellitus model animal, KK-Ay mice. The blood glucose levels of KK-Ay mice were maintained in a normal range during the administration of both complexes. After the administration of each complex for 14 d, the improvement of glucose metabolism was confirmed as judged by the glucose tolerance test.
Nickel-catalyzed carboxylation of aryl and heteroaryl fluorosulfates using carbon dioxide
Ma, Cong,Zhao, Chuan-Qi,Xu, Xue-Tao,Li, Zhao-Ming,Wang, Xiang-Yang,Zhang, Kun,Mei, Tian-Sheng
, p. 2464 - 2467 (2019/04/10)
The development of efficient and practical methods to construct carboxylic acids using CO2 as a C1 synthon is of great importance. Nickel-catalyzed carboxylation of aryl fluorosulfates and heteroaryl fluorosulfates with CO2 is described, affording arene carboxylic acids with good to excellent yields under mild conditions. In addition, a one-pot phenol fluorosulfation/carboxylation is developed.
Synthesis of Esters by Functionalisation of CO2
-
Paragraph 0129, (2017/09/06)
The invention relates to a method for (I) producing a carboxylic ester of formula (I). Said method comprises the steps of: a) bringing an organosilane/borane of formula Si or B into contact with CO2, in the presence of a catalyst and an electrophilic compound of formula (III), the groups R1, R2, R3, R4, R5, Y, and M′ being as defined in claim 1; and optionally b) recovering the compound of formula (I) produced.
Polysubstituted pyridine medical intermediate and synthetic method thereof
-
, (2016/10/08)
The invention belongs to the field of medicine intermediate technology, and specifically relates to a polysubstituted pyridine medical intermediate and a synthetic method thereof. The polysubstituted pyridine medical intermediate is a key intermediate in pharmaceutical synthesis, and has a huge market potential. The synthetic method has simple synthetic route, simple and easily available staring material, and has great meaning in synthesis of pyridine intermediate, development of pyridine medicament and research and development of novel medicament, and the product is cheap.
CO2 Conversion into Esters by Fluoride-Mediated Carboxylation of Organosilanes and Halide Derivatives
Frogneux, Xavier,Von Wolff, Niklas,Thuéry, Pierre,Lefèvre, Guillaume,Cantat, Thibault
, p. 2930 - 2934 (2016/03/25)
A one-step conversion of CO2 into heteroaromatic esters is presented under metal-free conditions. Using fluoride anions as promoters for the C-Si bond activation, pyridyl, furanyl, and thienyl organosilanes are successfully carboxylated with CO2 in the presence of an electrophile. The mechanism of this unprecedented reaction has been elucidated based on experimental and computational results, which show a unique catalytic influence of CO2 in the C-Si bond activation of pyridylsilanes. The methodology is applied to 18 different esters, and it has enabled the incorporation of CO2 into a polyester material for the first time. Metal free! A novel methodology is described to convert CO2 into heteroaromatic esters in the presence of organosilanes and organic halides using fluoride anions as promoters for the C-Si bond activation (see scheme). CO2 exhibits a unique catalytic influence in the C-Si bond cleavage of pyridylsilanes, serving as a traceless activator.
TRIAZOLE AGONISTS OF THE APJ RECEPTOR
-
Paragraph 0349, (2016/12/07)
Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.
Two-way linkage photoisomerization of [Ru(2,2':6',2''-terpyridine)(6- {(methylsulfinyl)methyl}picolinate)]BF4
Suzuki, Shoko,Sakamoto, Ryota,Nishihara, Hiroshi
, p. 17 - 18 (2013/03/14)
[Ru(tpy)(picSO)]BF4 (tpy: 2,2':6',2''-terpyridine, picSO: 6- [(methylsulfinyl)methyl]picolinate) undergoes profound linkage isomerization behavior between stable S-bound and metastable O-bound isomers. S-[RuII(tpy)(picSO)]BF4 experiences photoisomerization to O-[RuII(tpy)(picSO)] BF4 upon irradiation with 436nm light, whereas the back reaction is triggered with 546nm light. Electrochemical linkage isomerization also takes place.
NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
Paragraph 0713-0714, (2013/10/22)
This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R1, R2, R4, R6, E, n, Y1, Y2, Y3, Y4, Y5, L, B, R8, and m are as defined in the claims.
NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF
-
Page/Page column 118-119, (2013/04/24)
The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
